---
title: "EVFM: Innovative women's health products achieve growth, global expansion, and cost optimization"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293229761.md"
description: "Two FDA-approved products, PHEXX and SOLOSEC, are driving revenue growth and expanding globally, supported by strong IP and targeted marketing. Cost reduction initiatives and new international partnerships aim to boost profitability and broaden market reach.Original document: Evofem Biosciences, Inc. [EVFM] Slides Release — Jul. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-20T14:35:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293229761.md)
  - [en](https://longbridge.com/en/news/293229761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293229761.md)
generator: "portal-rs"
---

# EVFM: Innovative women's health products achieve growth, global expansion, and cost optimization

Two FDA-approved products, PHEXX and SOLOSEC, are driving revenue growth and expanding globally, supported by strong IP and targeted marketing. Cost reduction initiatives and new international partnerships aim to boost profitability and broaden market reach.

Original document: Evofem Biosciences, Inc. \[EVFM\] Slides Release — Jul. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [EVFM.US](https://longbridge.com/en/quote/EVFM.US.md)

## Related News & Research

- [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md)
- [The Bot Now Clicks Buy: Your AI Is About To Start Spending Your Money](https://longbridge.com/en/news/297424265.md)
- [Adam Schiff Says AI Companies 'Shouldn't be Able to Push Their Costs Off Onto Everyday Americans,' Calls For Progressive Tax Code](https://longbridge.com/en/news/297419733.md)
- [CLYM: CLYM116 Phase 1 data show durable APRIL suppression and support Q12W dosing in IgA nephropathy](https://longbridge.com/en/news/297903827.md)
- [STR: 2030 targets raised to €30 billion output and ≥6% EBIT margin, backed by record order backlog](https://longbridge.com/en/news/297647662.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**